Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and maprotiline

moxifloxacin has been researched along with maprotiline in 4 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(maprotiline)		Trials
(maprotiline)		Recent Studies (post-2010) (maprotiline)
3,1575521,69093321159

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)maprotiline (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.078
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)0.03
Muscarinic acetylcholine receptor M2Homo sapiens (human)1.927
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.413
Cytochrome P450 3A4Homo sapiens (human)4.322
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.16
Alpha-2A adrenergic receptorHomo sapiens (human)1.824
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.593
D(2) dopamine receptorHomo sapiens (human)3.463
Alpha-2B adrenergic receptorHomo sapiens (human)0.292
Alpha-2C adrenergic receptorHomo sapiens (human)3.044
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.473
D(1A) dopamine receptorHomo sapiens (human)0.373
Sodium-dependent noradrenaline transporter Homo sapiens (human)0.03
Histamine H2 receptorHomo sapiens (human)0.4
Alpha-1D adrenergic receptorHomo sapiens (human)0.397
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.064
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.078
Histamine H1 receptorHomo sapiens (human)0.0088
D(3) dopamine receptorHomo sapiens (human)0.645
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.336
5-hydroxytryptamine receptor 6Homo sapiens (human)0.892
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)10
Sodium-dependent dopamine transporter Homo sapiens (human)2.91

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for moxifloxacin and maprotiline

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for moxifloxacin and maprotiline

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10

    Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers

2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014